BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) presented clinical data for its hereditary angioedema treatments at the European Academy of Allergy and Clinical Immunology Annual Meeting in Istanbul from June 12-15.

The company shared 48-week data from the APeX-P study evaluating ORLADEYO in pediatric HAE patients aged 2 to under 12 years. The median adjusted HAE attack rate requiring on-demand treatment decreased from 0.691 attacks per month during a 12-week standard of care period to 0.169 attacks per month during 48 weeks of ORLADEYO treatment. HAE attacks requiring professional care dropped from 22 during the standard of care period to 3 over 12 weeks of ORLADEYO treatment.

BioCryst also presented a post hoc analysis of its Phase 1b/2 ALPHA-STAR study of investigational navenibart, a monoclonal antibody plasma kallikrein inhibitor. The analysis showed reductions in overall HAE attack rates across patient subgroups defined by baseline attack rate, body mass index, and age. Reductions in moderate or severe attacks were observed across all BMI subgroups.

The company presented real-world evidence data from multiple studies demonstrating ORLADEYO's ability to reduce HAE burden in routine clinical practice. The studies showed benefits in adolescent and adult patients, including those switching from other long-term prophylaxis therapies, with reduced healthcare resource utilization.

ORLADEYO is the first oral therapy designed to prevent HAE attacks in adult and pediatric patients 2 years and older. Navenibart is currently being evaluated in Phase 3 trials as a potential long-acting therapeutic option with dosing every 3 or 6 months.